Scarica l'app Stockscreener
14.58
1.67%
0.24
Dopo l'orario di chiusura:
14.50
-0.08
-0.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.34
Aprire:
$14.24
Volume 24 ore:
8.46M
Relative Volume:
0.97
Capitalizzazione di mercato:
$16.79B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-4.5994
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+11.38%
1M Prestazione:
+17.58%
6M Prestazione:
+66.63%
1 anno Prestazione:
+33.76%
Intervallo 1D:
$14.10
$14.60
Intervallo di 1 settimana:
$13.00
$14.60
Portata 52W:
$6.85
$14.60
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.58 | 16.52B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance UK
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris Announces Chief Legal Officer Transition and Successor - TipRanks
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $13.49 - Investing.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What Are Wall Street Analysts' Target Price for Viatris Stock? - Yahoo Finance
What Does the Market Think About Viatris Inc? - Benzinga
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com UK
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com Nigeria
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Viatris launches ‘EmpowerED for Life’ for men’s health in Africa - MSN
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch - Yahoo Finance
Viatris Earnings Preview: What to Expect - Barchart.com
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria
Viatris launches heart failure drug Inpefa in UAE, first outside US By Investing.com - Investing.com South Africa
3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Finviz
Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途牛牛
Viatris Launches Inpefa in United Arab Emirates - marketscreener.com
Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq
Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Contact UsCeres CourierViatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):